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Abstract 
Background  It is debatable whether treating multimorbid nursing home patients with antihypertensive drugs produces beneficial effects. 
Most cardiovascular guidelines promote treatment; few have advice on how to deprescribe when treatment may no longer be necessary. We inves-
tigated the effect of medication review on antihypertensive drug use and the association between cognition, blood pressure, and prescribing. 
Methods  From August 2014 to December 2015, 765 patients from 72 units (clusters) in 32 Norwegian nursing homes were included in a 
4-month, multicentre, cluster-randomized, controlled trial, with 9-month follow-up. Patients ≥ 65 years old with antihypertensive treatment (n = 
295, 39%) were randomized to systematic medication review where the physician received support from peers (collegial mentoring) or were 
given care as usual (control condition). Outcome measures were the number of antihypertensive drugs, systolic blood pressure, and pulse. We 
used hospitalizations and deaths as criteria to assess harm. Results  At baseline, each patient used 9.2 ± 3.5 regular drugs, and 1.6 ± 0.7 anti-
hypertensives. Mean blood pressure was 128/71 mmHg and 9% had a systolic pressure ≥ 160 mmHg. Between baseline and month four, anti-
hypertensives were deprescribed to a significantly higher extent in the intervention group (n = 43, 32%) compared to control (n = 11, 10%); Inci-
dence Rate Ratio = 0.8, 95% CI = 0.70.9. In the intervention group, there was an immediate increase in systolic blood pressure when anti-
hypertensives were reduced, from baseline 128 ± 19.5 mmHg to 143 ± 25.5 mmHg at month four. However, at month nine, the blood pres-
sure had reverted to baseline values (mean 134 mmHg). Deprescription did not affect pulse and systolic pressure. The number of hospitalizations 
was higher in control patients at month four (P = 0.031) and nine (P = 0.041). Conclusion  A systematic medication review supported by 
collegial mentoring significantly decreased the use of antihypertensive drugs in nursing home patients without an effect on the systolic blood 
pressure over time. 
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1  Introduction 
Cardiovascular diseases such as hypertension, heart fail-
ure, and atrial fibrillation affect almost half the residents 
living in a nursing home.[1,2] Dementia affects over 80%.[3] 
While previous treatment with antihypertensives, beta-blocker 
or diuretics may have been beneficial, this treatment is often 
no longer necessary, or may even be harmful, when frail old 
patients approach the end of life. Multimorbidity combined 
with polypharmacy and increased risk of adverse events 
requires a patient-centred, individually adapted approach.  
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International guidelines by the European Society of Hy-
pertension and the American Eight Joint National Commit-
tee state that only the treatment of hypertension grade two 
and above (systolic blood pressure ≥ 160 mmHg) is shown 
to reduce cardiovascular events in fit elderly people over 80 
years old.[4,5] Meanwhile, these recommendations do not 
cover the treatment of hypertension in the more fragile 
group of nursing home patients and people with dementia, 
who are often excluded from clinical studies[6] and are 
high-consumers of antihypertensives.[7] Treatment may lead 
to orthostatic hypotension, falls, and increased anticholiner-
gic burden in this population.[8] 
Nursing home patients were excluded from the two ma-
jor trials exploring effects of antihypertensive treatment in 
the oldest population,[9,10] however some smaller studies 
have included these patients: a prospective study on 406 
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Swedish nursing home patients shows that lower systolic 
blood pressure was associated with increased mortality.[11] 
Another non-randomized controlled trial of deprescribing in 
general included 190 Israeli nursing home patients found 
successful deprescribing of cardiovascular drugs without 
increased blood pressure or mortality.[12] 
Given that antihypertensives are used to treat a range of 
different indications beyond hypertension, such as angina 
pectoris, rhythm control in atrial fibrillation and renal failure, 
treatment requires individual diagnostic and clinical evalua-
tion of the patient that also includes his or her values and 
preferences on treatment-goals.[13] For patients with demen-
tia, involving the relatives as the patient’s spokesperson is 
relevant. In a person-centred approach, deprescribing also 
entails close monitoring of the blood pressure, pulse and 
other adverse events before and after the change of the 
treatment to avoid potential harm.[14]  
The current study aimed to optimize the antihypertensive 
treatment for nursing home patients through systematic 
medication reviews supported by collegial mentoring. The 
primary objective of this paper is to investigate how indi-
vidual person-centred care affects the use of antihyperten-
sives. Secondary objectives were to assess the effect of 
changes in antihypertensive drugs on blood pressure and 
pulse after four and nine months, and to investigate whether 
baseline blood pressure or cognitive status could predict 
change.  
2  Methods 
2.1  Study design 
This paper presents data from the COSMOS study, a 
multicentre, cluster-randomized controlled trial executed in 
Norwegian nursing homes between August 2014 and De-
cember 2015. COSMOS is a complex intervention study 
where the interventions are denoted by the acronym COS-
MOS: COmmunication, Systematic pain assessment and 
treatment, Medication review, Organization of activities, 
and Safety. The implementation process and sample-size 
analyses are described in detail in the published protocol.[15] 
The COSMOS study aimed to improve patients’ quality of 
life. It also sought to improve neuropsychiatric symptoms 
such as agitation, depression and sleep. Other secondary 
aims were to improve the activities of daily living, pain, 
prescribing routines and costs for nursing home patients. In 
this paper, we focus on the effect of the systematic medica-
tion review involving collegial mentoring, especially anti-
hypertensive drug prescription.  
We initially invited 37 Norwegian nursing homes located 
in eight municipalities to participate in this study. Munici-
palities were of different size and location and the nursing 
homes housed between 16 and 150 patients living in 72 
units (clusters) (Figure 1). Only nursing home units with 
long-term care patients were included. To be included in the 
present study, the patients had to use antihypertensive drugs 
at baseline and be 65 years or older. We excluded dying 
patients and those with schizophrenia. 
We chose a cluster design to account for patients in the 
same units receiving comparable treatment. Each unit was 
defined as a cluster and was randomized with a random 
number sequence in SPSS 18 (IBM, Armork, NY), stratified 
by geographical location. The nature of the intervention 
prevented blinding of staff or researchers.  
2.2  Intervention and control conditions 
To implement the complex COSMOS intervention, a 
two-day educational seminar gathered all nursing home 
units randomized to the intervention group. The units sent at 
least two nurses elected to be the unit’s COSMOS ambas-
sadors. In addition, other nurses from the unit, the unit 
manager, the responsible physicians and a pharmacist were 
invited. The education program covered research-based 
knowledge about communication with relatives and patients 
through advance care planning, pain assessment and treat-
ment, the rationale and method for multidisciplinary medi-
cation review, and organization of activities for all included 
patients. The education program also included role-playing 
and patient-centred discussions. At the seminar, the COS-
MOS ambassadors received educational material to train the 
other staff in the unit. 
Regarding the medication review, we especially empha-
sized that the patient’s clinical test results pertaining to 
blood pressure, pulse, blood tests, neuropsychiatric symp-
toms, cognitive status, activities of daily living function, 
pain, well-being, and symptom relief should inform drug- 
decision-making. In addition, the patient’s and relatives 
wishes were considered. For example, if a patient was 
evaluated as not being in pain, the physician was encour-
aged to temporarily suspend the pain medication. Treatment 
changes should be communicated to the staff and patient (if 
possible). The staffs were also instructed to also inform the 
relatives. Every change had to be followed by re-assess-
ment.  
After the seminar, the COSMOS ambassadors trained the 
rest of the staff in their units.[16] The training sessions had a 
duration of approximately 15 min every day and included 
all staff in the unit. The ambassadors were instructed to fo-
cus on one component per week: communication, sys- 
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Figure 1.  Flow chart of the study. 
tematic pain assessment and treatment, medication reviews, 
and organization of activities. For the medication review in 
particular, the physicians received a separate booklet with a 
short description of the assessment tools used in the medica-
tion reviews, the Norwegian guidelines for medication re-
views,[17,18] the updated STOPP/START criteria for poten-
tially inappropriate prescribing in older people,[19] and a list 
of anticholinergic drugs.[20] 
In addition to the seminars, experienced researchers vis-
ited each unit and trained at least two nurses in the neces-
sary clinical assessments in four-hour sessions.[15] The 
nurses learned how to use the instruments to evaluate their 
patients and how to interpret the results. These assessments 
informed the medication reviews, in addition to data from 
medical records, blood samples, and diagnoses. 
The researchers scheduled a meeting with the physician 
and nurse in each unit to perform medication reviews on the 
patients. Before the medication reviews, the staff assessed 
cognitive function, neuropsychiatric symptoms, pain, activi-
ties of daily living, and quality of life in all patients, using 
tools validated for people with dementia.[15] This informa-
tion, together with information on diagnoses, drug-drug 
interactions, blood pressure, pulse, and lab tests were used 
to assess medication lists. We used the START/STOPP 2 
criteria and the available clinical observations to guide revi-
sions.[19] The criteria recommend treating with antihyper-
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tensives if systolic blood pressure is ≥ 160 mmHg. We 
recommended dose tapering or withdrawal of drugs if the 
blood pressure was below the recommended limit. We also 
recommended deprescribing if the patients overall condition 
was deteriorating, if the patient was unwilling to allow 
monitoring of treatment, or if the patient had a short life-ex-
pectancy.[21] The physician ordered relevant blood tests, and 
the nurse checked the drugs in an interaction database.[22] 
The physician was in charge of all medical decisions in the 
meeting; the nurse provided updated knowledge about the 
patients’ situation, and the researcher gave provided deci-
sion support by initiating discussions, giving support in dif-
ficult decisions and supplementing with relevant research on 
the field (collegial mentoring). The discussions around 
treatment had a patient-centred focus.  
The control units continued treatment and provided care 
as usual. After data collection at month nine, the control 
units underwent the same education programme as the in-
tervention units.  
2.3  Data collection 
All patients were assessed at baseline, month four and 
month nine. Data on prescribed drugs, diagnoses, blood 
pressure, pulse and hospital admissions were obtained from 
the medical records. The nurses in the units performed the 
data extraction from medical records and measured blood 
pressures and pulse. The researchers tested all patients with 
Mini Mental Status Examination (MMSE).[23] Drugs were 
coded to the fifth level of the Anatomical Therapeutic 
Chemical Index (ATC) classes and presented as the number 
of drugs in each fourth level class.[24] The diagnoses col-
lected from the medical records were coded according to 
The International Classification of Primary Care (ICPC).[25] 
2.4  Outcome measures 
Hypertension was defined as the ICPC diagnoses K85 
Elevated blood pressure, K86 Uncomplicated hypertension, 
and K87 Hypertension with organ complications. The 
number of antihypertensives comprised the sum of drugs 
used within the following five drug classes: C03C High 
Ceiling Diuretics (loop-diuretics), C07A Beta Blockers, 
C09A Plain Angiotensin-Converting-Enzyme Inhibitors, 
C09C Plain Angiotensin II Antagonists, and C08C Calcium 
Channel Blockers with mainly vascular effect. These drugs 
were the most prescribed drugs with hypertension as one of 
their main indications, but may also be prescribed for other 
indications such as heart failure, angina pectoris, rhythm 
control in atrial fibrillation, and renal failure. Twelve or 
fewer patients individually used other antihypertensive drug 
classes. The nurses in the units measured blood pressure in 
mmHg according to the local procedure. In one analysis, the 
blood pressure at baseline was dichotomized into high or 
normal/low. The systolic and diastolic cutoffs for high 
blood pressure were ≥ 160 mmHg and ≥ 90 mmHg, respec-
tively. Deprescribing antihypertensive drugs was defined as 
using fewer antihypertensive drugs at month four than at 
baseline. Cognitive function was divided into four groups 
according to MMSE results at baseline―severe dementia, < 
11; moderate, 1120; mild, 2125; and no dementia: > 
25.[26]  
2.5  Statistical analyses 
For regression analyses with total number of antihyper-
tensive drugs as the outcome, we used multilevel mixed 
effects Poisson regression. These analyses were: (1) anti-
hypertensive drug use over time for intervention and control, 
with random effects of time and group; (2) the effect of a 
high vs. low/normal systolic or diastolic blood pressure on 
antihypertensive drug use, with fixed effect for blood pres-
sure at baseline, and random effect of time; and (3) the ef-
fect of baseline cognitive function on antihypertensive drug 
use, with fixed effect for cognitive function at baseline, and 
random effect of time. In analyses 1−3, we used robust 
standard errors to account for deviations from assump-
tions.[27] Analyses 2 and 3 were stratified by group alloca-
tion due to different change over time in these two groups. 
Linear mixed models were used to investigate the effect of 
reducing antihypertensive drugs on (4) systolic blood pres-
sure, (5) diastolic blood pressure, and (6) pulse. Analyses 
4–6 used fixed effect for deprescribing and random effects 
of time. Analyses 4–6 were only performed in the interven-
tion group because of too few deprescriptions in the control 
group. All analyses used random intercepts for patients and 
units, and patients were nested within units. Chi square tests 
were used to test potential differences in hospital admissions. 
All P-values were two-sided and significance was set at < 
0.05. STATA 14.2 (StataCorp, Texas, USA) was used for 
all analyses.  
3  Results 
In total, 295 patients used antihypertensive drugs at base-
line, 164 in the intervention group and 131 in the control 
group (Figure 1). Age, number of recorded diagnoses, the 
total number of drugs and types of antihypertensive drug 
used were similar across the groups (Table 1). Sixty-four 
(39%) patients in the intervention and 55 (42%) of the con-
trol group had a diagnosis of hypertension. A cardiovascular 
diagnosis was recorded in 216 (79%) patients. In addition to 
hypertension, the most frequent diagnoses were atrial fibrilla-  
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Table 1.  Demographics of included patients at baseline. 
Intervention n = 164 Control n = 131 
Variables 
  Min to Max   Min to Max 
Females 115 (70%)     90 (69%)   
Age 86.9 ± 7.6 66104 87.5 ± 7.2 67102 
*Mini mental status examination 11.7 ± 7.4 028 13.2 ± 7.6 029 
Severe dementia 72 (53%)   44 (43%)   
Moderate dementia 46 (34%)   37 (36%)   
Mild dementia 10 (7%)   11 (11%)   
No dementia 8 (6%)   11 (11%)   
Number of diagnoses 4.8 ± 3.5 014 5.2 ± 3.8 027 
Number of regular prescriptions 9.2 ± 3.4 219 9.1 ± 3.6 321 
Number of antihypertensive drugs 1.6 ± 0.7 14 1.6 ± 0.7 14 
C03C high-ceiling diuretics 97 (59%)    68 (52%)   
C07A beta-blockers 81 (49%)    67 (51%)   
C09C plain angiotensin II antagonists 35 (21%)     27 (21%)    
C09A plain ACE inhibitors 29 (18%)     26 (20%)    
C08C calcium channel blockers, mainly vascular effect 21 (13%)    19 (15%)   
Blood pressure       
High systolic blood pressure 14 (8%)   9 (7%)   
Systolic, mean mmHg 128 ± 20.4 77196 128 ± 20.3 90190 
Diastolic, mean mmHg 71 ± 12.3 38103 71 ± 12.9 40117 
Pulse, beats per minute 70 ± 12.0 40110 71 ± 12.1 44109 
Data are presented as mean ± SD or n (%). *Mini Mental Status Examination range: 030. ACE: angiotensin converting enzyme. 
 
tion in 109 (23%) patients, heart failure in 50 (17%) patients, 
and stroke in 46 (16%) patients. The patients were treated 
by 36 different physicians in 20 units; six of the physicians 
attended both intervention and control units. No pharmacists 
attended the study. 
Both intervention and control patients used on average 
1.6 ± 0.7 antihypertensives. In the intervention group, 14 
(8%) had hypertension (systolic pressure ≥ 160 mmHg), and 
nine (5%) had hypotension (systolic pressure < 100 mmHg); 
in the control patients, these figures were 9 (7%) and 5 (4%), 
respectively. The number of antihypertensive drugs were 
reduced in 43 (32%) (Table 2) intervention group patients 
[incidence rate-ratio (IRR) = 0.8, 95% CI = 0.70.9] from 
baseline to month four, compared to a reduction in 11 (10%) 
control group patients (IRR = 0.9, 95% CI = 0.91.0) (Table 
3). The reduction was greater in intervention than in control 
patients (IRR = 0.8, 95% CI = 0.70.9) (Figure 2). Three of 
37 intervention patients with a reduction in antihyperten-
sives from baseline to month four had antihypertensive 
drugs reinstated (Table 2). There were no significant 
changes in use of antihypertensives between month four and 
month nine (Table 3). Diuretics and beta-blockers were re-
duced most (Figure 2).  
Patients in the intervention group with a reduction in an-
tihypertensive drugs from baseline to month four had an 
increase in their systolic blood pressure from 128 ± 19.5 to 
143 ± 25.5 mmHg (mean difference = 14, 95% CI: 7.721.2) 
(Table 3). By month nine, the mean blood pressure had re-
turned to its initial level, with no significant difference be-
tween baseline and month nine assessments (mean differ-
ence = 6, 95% CI: 1.9 to 14.6). There were no significant 
changes in blood pressure for patients staying on antihyper-
tensive drugs (Table 3). The trends were similar for diastolic 
blood pressure, data not shown. Pulse was not affected by 
deprescribing (Table 3).  
Table 2.  Use of antihypertensives in patients with data at all 
three time points. 
Development Intervention Control
Decrease between baseline and month four 37 6 
Reduction to month nine 0 1 
No change month nine 34 5 
Increase to month nine 3 0 
No change between baseline and month four 80 83 
Reduction to month nine 10 11 
No change month nine 68 72 
Increase to month nine 2 0 
Increase between baseline and month four 1 1 
Reduction to month nine 0 0 
No change month nine 1 1 
Increase to month nine 0 0  
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Table 3.  Tests of change in antihypertensive prescribing, blood pressure and pulse over nine months. 
 Change between baseline and month four Change between month four and month nine 
Variables 
 Intervention Control Intervention Control 
*Antihypertensive drugs, IRR (95% CI) 0.8 (0.70.9) 0.9 (0.91.0) 0.9 (0.91.0) 0.9 (0.81.0) 
#High blood pressure, IRR (95% CI) 1.0 (0.91.2) 0.7 (0.51.0) 1.0 (0.91.2) 1.1 (0.52.5) 
†Cognitive status, IRR (95% CI)        
Severe dementia 1   1  1   1  
Moderate dementia 1.1 (1.01.4) 1.0 (0.91.2) 1.0 (0.81.2) 1.1 (0.81.3) 
Mild dementia 1.0 (0.81.3) 1.0 (0.91.2) 1.1 (0.81.7) 1.1 (0.81.4) 
No dementia 1.2 (1.01.5) 1.0 (0.91.2) 1.1 (0.91.4) 0.7 (0.41.3) 
§Systolic blood pressure, beta (95% CI)           
No antihypertensives described, n = 93 2 (6.3 to 2.6)    2 (2.9 to 6.4) 2   
Antihypertensives deprescribed, n = 43 14 (7.721.2)    8 (15.2 to 1.2) 8   
¤Pulse, beta (95% CI)           
No antihypertensives described, n = 93 0 (2.73.5)    0 (3.1 to 3.5)    
Antihypertensives deprescribed, n = 43 2 (2.96.5)    0 (5.4 to 4.4)    
*Multilevel Poisson regression with IRR representing change in antihypertensive drug use; #Multilevel Poisson regression with IRR representing change in antihyper-
tensive drug use for patients with high blood pressure compared to low/normal blood pressure; †Multilevel Poisson regression with IRR representing change in anti-
hypertensive drug use between the different levels of cognitive function at baseline; §Multilevel linear regression with betas representing change in blood pressure 
between baseline and month four; ¤Multilevel linear regression with betas representing change in pulse between baseline and month four. IRR: incidence rate ratios. 
 
Figure 2.  Use of antihypertensives at baseline, month four, and month nine. Percentages describe proportion of patients in each group 
using the drug. ACE: angiotensin converting enzyme. 
Patients with a systolic blood pressure ≥ 160 mmHg at 
baseline had the same reduction in number of antihyperten-
sive drugs as patients with blood pressure < 160 mmHg 
(Table 3). There were no differences in deprescribing accord-
ing to the different levels of cognitive function (Table 3).  
Between baseline and month four, seven (5%) patients in 
the intervention group were admitted to the hospital and 19 
(12%) died, while in the control group, 14 (13%) were ad-
mitted to the hospital and 17 (13%) died. Between month 
four and month nine, seven (6%) intervention group patients 
were hospitalized, and 17 (12%) died; corresponding figures 
for control group patients were 12 (13%) and 12 (11%) re-
spectively. Hospitalization was significantly higher for con-
trols at month four (P = 0.031) and month nine (P = 0.041). 
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4  Discussion 
To our knowledge, this is the largest study on depre-
scribing antihypertensive drugs in nursing home patients 
with follow-up assessment of blood pressure over time. In-
dependently of cognitive impairment, participants used 1.6 
antihypertensive and in 32%, the drug regime was reduced 
following a person-centred care intervention. Over the next 
four months, the systolic blood pressure increased by 14 
mmHg, however, at month nine, blood pressure had re-
turned to baseline levels. The findings are of key importance 
for the clinician since collegial mentoring and re-assessment 
of the patient’s blood pressure may decrease critical harms 
such as orthostatic hypotension, falls, and anticholinergic 
side effects. Especially, when keeping in mind that over 40% 
of Norwegian nursing home residents die in the first six 
months after admission, only 30% live more than two years, 
and over 80% have dementia.[3] 
The mean baseline blood pressure in our patients was 
comparable to earlier findings,[11,28] and the deprescribing 
procedures were conducted irrespective of hyper-, hypo-, or 
normotensive states. Not surprisingly, and in line with ear-
lier observations,[29,30] the blood pressure increased after 
discontinuation, but mean pressure was still below the indi-
cation for treatment.[4,5] We also observed that the blood 
pressure decreased to initial levels after nine months, but the 
causality for this development is still uncertain. A Swedish 
nursing home study following 180 participants over 18 
months found that the systolic blood pressure decreased by 
about 5 mmHg during the study period irrespective of any 
changes in cardiovascular drug prescriptions.[11] A steady de-
crease over time might therefore be expected in nursing home 
patients, and can explain the fall we experienced from month 
four to nine.  
Beta-blockers and diuretics were the two drug groups that 
were most frequently deprescribed. Importantly, the reduction 
did not affect pulse throughout the study period. These drugs 
are also indicated in other cardiovascular diagnoses like atrial 
fibrillation and heart failure. However, more than 20% of the 
participants lacked a cardiovascular diagnosis. This is par-
ticularly alarming because beta-blockers and diuretics cause 
hypotension in 34% of elderly people at daytime and in 
9% during the night, and they might even increase morta-
lity.[31,32] As discussed in the introduction, the guidelines are 
vague in their recommendations for antihypertensive treat-
ment of the fragile old.[4,5] Hence, effect of antihypertensive 
treatment for this group can be debated. Antihypertensive 
drugs are a major contributor to polypharmacy,[2] and poly-
pharmacy is related to inappropriate prescribing, hospitaliza-
tions and side effects.[33] Reducing drugs with debatable po-
tential benefits is a sensible approach when addressing poly-
pharmacy. Another important element is to reduce drugs be-
fore the patient is too debilitated to swallow, by doing this we 
can reduce harmful effects of tapering.[34] 
Our systematic medication review included the standard-
ized training of nursing home staff, collegial support of nurs-
ing home physicians, and drug optimizing by person-centred 
care.[13] Contrary to other researchers, we did not introduce a 
new profession or recruit external aid from outside the nursing 
homes after the study period.[33] Consequently, we expected 
that the effect of collegial mentoring, multidisciplinary col-
laboration between physicians and nursing staff, and educa-
tion would last beyond the four-month period. However, our 
results demonstrated that the main effects were concentrated 
between baseline and month four, and that significant differ-
ences between the intervention and control units diminished 
over time. Sustained collaboration, education, and learning are 
crucial prerequisites for person-centred care.[13] 
This was a cluster-randomized trial, implying that total 
blinding of the healthcare staff is not possible. This may also 
explain a reduction of antihypertensives in the control groups. 
Another limitation may be that randomization of units―rather 
than physicians (six doctors were working in both intervention 
and control units)―possibly decreased the differences be-
tween the two groups. Furthermore, standard routines for 
measuring blood pressure are not well established in nursing 
homes. Our reliance on local routines may suggest an amount 
of uncertainty in the blood pressure results. Our study did not 
consider change in dosages that may have affected the clinical 
outcomes. The hospitalization rate was slightly higher in the 
control group, without significant differences in death rates; 
this might be a result of the advance care planning part of 
COSMOS.[15] At the same time, we did not systematically 
register adverse events like strokes or heart failure, so it is 
unclear whether the reductions may have caused additional 
events. 
The transferability of the results is strengthened by a com-
prehensive sample size and the variety of units involved, as 
well as the individualized approach to medication optimiza-
tion. Future research should focus on method development 
and validation of implementation processes.  
4.1  Conclusions 
Nursing home patients use numerous antihypertensive 
drugs with potential side effects and uncertain indication. 
The implementation of an individualized medication review 
decreased the use of antihypertensives. The change in drug 
prescription led to a temporary increase in the systolic blood 
pressure, which returned to initial readings over the study 
period. Multidisciplinary staff education, collegial mentor-
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ing, and person-centred care are crucial prerequisites for 
decision-making in connection with the medication review 
procedure.  
4.2  Compliance with Ethical Standards 
All procedures performed in studies involving human 
participants were in accordance with the ethical standards of 
the institutional and/or national research committee and 
with the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards. We provided information 
about the study both orally and in writing to all patients and 
their next of kin. Patients who were able signed informed 
consent forms. When patients lacked the competence to 
provide consent, the next of kin provided presumed written 
consent on behalf of the patient. The Helsinki declaration 
was followed and the Regional Ethics Committee, West 
Norway approved the approach (2013/1765). The article 
follows the CONSORT guidelines on reporting cluster- 
randomized trials.[35, 36] The trial was registered at clinical-
trials.gov (NCT02238652), 7 July 2014. 
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